AKB 4924

Drug Profile

AKB 4924

Alternative Names: AKB-4924

Latest Information Update: 29 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Developer Aerpio Pharmaceuticals
  • Class Anti-inflammatories; Piperazines; Pyridones; Small molecules
  • Mechanism of Action EGLN2 protein inhibitors; Hypoxia inducible factor 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 15 Mar 2017 Zeta Acquisition Corp II in a reverse merger transaction acquires Aerpio Therapeutics and changes its name to Aerpio Pharmaceuticals
  • 01 Jan 2017 Aerpio Therapeutics completes a phase I trial in Healthy volunteers in Canada (NCT02914262)
  • 01 Aug 2016 Phase-I clinical trials in Inflammatory bowel disease (In volunteers) in Canada (PO) (NCT02914262)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top